| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 26.40 | -0.10 (-0.38%) | 7.07 - 31.15 | 19.7 thousand (Above Avg) |
Market data as of 4:00PM 05/22/13. Quotes are delayed by at least 15 min.
| Open | 26.50 |
|---|---|
| Previous Close | 26.50 |
| Day's Range | 26.35 - 26.50 |
| Market Cap | 708.7M |
| Avg Volume (10 Day) | 16.0K |
| Price/Earnings (Trailing 12 Mo.) | 15.6x |
| Earnings Per Share (Trailing 12 Mo.) | 1.7 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
China Biologic Reports Financial Results for the First Quarter of 2013
PR Newswire - Wednesday 05/08/2013 5:00 PM ET
China Biologic Products to Report First Quarter 2013 Financial Results
PR Newswire - Thursday 05/02/2013 4:01 PM ET
China Biologic's Shandong Taibang Subsidiary Donates Lifesaving Plasma Products for the Injured in the Ya'an Earthquake
PR Newswire - Wednesday 04/24/2013 8:54 AM ET
| CBPO | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 15.54% | |
| Net Income Growth (1yr) | 53.09% | |
| Total Debt/Equity | 0.04 | |
| LT Debt/Equity | 0.02 | |
| Earnings Yield | 6.41% | |
| Price/Sales | 3.71 |
| Company | Last | Change |
|---|---|---|
| Optimer Pharmaceuticals Inc | 14.39 | -0.28% |
| Exact Sciences Corp | 10.58 | -1.67% |
| Array Biopharma Inc | 5.80 | -1.36% |
| Achillion Pharmaceuticals Inc | 7.74 | -0.13% |
| Dendreon Corp | 3.95 | -0.25% |
Data is delayed by at least 15 min.